KR20230148144A - Kras 돌연변이 암의 치료 - Google Patents

Kras 돌연변이 암의 치료 Download PDF

Info

Publication number
KR20230148144A
KR20230148144A KR1020237020122A KR20237020122A KR20230148144A KR 20230148144 A KR20230148144 A KR 20230148144A KR 1020237020122 A KR1020237020122 A KR 1020237020122A KR 20237020122 A KR20237020122 A KR 20237020122A KR 20230148144 A KR20230148144 A KR 20230148144A
Authority
KR
South Korea
Prior art keywords
days
cancer
boruciclib
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237020122A
Other languages
English (en)
Korean (ko)
Inventor
산드라 이. 와일리
다니엘 피. 골드
Original Assignee
메이 파마, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메이 파마, 아이엔씨. filed Critical 메이 파마, 아이엔씨.
Publication of KR20230148144A publication Critical patent/KR20230148144A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237020122A 2020-11-19 2021-11-19 Kras 돌연변이 암의 치료 Pending KR20230148144A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063115969P 2020-11-19 2020-11-19
US63/115,969 2020-11-19
US202163154652P 2021-02-26 2021-02-26
US63/154,652 2021-02-26
US202163158849P 2021-03-09 2021-03-09
US63/158,849 2021-03-09
US202163173361P 2021-04-10 2021-04-10
US63/173,361 2021-04-10
PCT/US2021/060151 WO2022109307A1 (en) 2020-11-19 2021-11-19 Treatment of kras mutant cancers

Publications (1)

Publication Number Publication Date
KR20230148144A true KR20230148144A (ko) 2023-10-24

Family

ID=81709695

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020122A Pending KR20230148144A (ko) 2020-11-19 2021-11-19 Kras 돌연변이 암의 치료

Country Status (9)

Country Link
US (1) US20240016781A1 (https=)
EP (1) EP4247806A4 (https=)
JP (1) JP2024500288A (https=)
KR (1) KR20230148144A (https=)
AU (1) AU2021381423A1 (https=)
CA (1) CA3198938A1 (https=)
IL (1) IL302925A (https=)
MX (1) MX2023005806A (https=)
WO (1) WO2022109307A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4376839A4 (en) * 2021-07-26 2025-10-15 Vincerx Pharma Inc SELECTIVE CDK9 INHIBITOR FOR THE TREATMENT OF RAS MUTANT CANCER
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
IL319991A (en) * 2022-10-03 2025-06-01 Prelude Therapeutics Inc Cancer treatment using combinations of SMARCA2 inhibitors and KRAS-targeted therapies
WO2024173833A1 (en) * 2023-02-16 2024-08-22 Mei Pharma, Inc. Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
CN105530931B (zh) * 2013-07-12 2019-11-08 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
US20220175750A1 (en) * 2018-04-23 2022-06-09 The Regents Of The University Of California Sustained release formulation for local delivery of cdk9 inhibitors
WO2020046966A1 (en) * 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2020271908B2 (en) * 2019-04-11 2025-12-04 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof
CA3148504A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
WO2022217133A1 (en) * 2021-04-10 2022-10-13 Mei Pharma, Inc. Voruciclib dosing regimens and methods of treatment including the same

Also Published As

Publication number Publication date
AU2021381423A1 (en) 2023-06-22
WO2022109307A1 (en) 2022-05-27
US20240016781A1 (en) 2024-01-18
EP4247806A4 (en) 2024-11-13
IL302925A (en) 2023-07-01
JP2024500288A (ja) 2024-01-09
CA3198938A1 (en) 2022-05-27
EP4247806A1 (en) 2023-09-27
AU2021381423A9 (en) 2024-02-08
MX2023005806A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
KR20230148144A (ko) Kras 돌연변이 암의 치료
TWI902129B (zh) 給予kras抑制劑治療癌症
US20210346382A1 (en) BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
KR20240019172A (ko) Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법
TWI428336B (zh) Ｐｉ３ｋ抑制劑及ｍｅｋ抑制劑之組合
JP2010539177A (ja) ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
WO2022170060A1 (en) Combination therapy for treating abnormal cell growth
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
EP3120851A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
TW202002983A (zh) 組合療法
JP7214632B2 (ja) ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
AU2022203204A1 (en) Use of heterocyclic pdk1 inhibitors
WO2024173761A1 (en) Combinations comprising mek inhibitors for use in the treatment of cancer
JP2018080179A (ja) ２−（４−（２−（１−イソプロピル−３−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）−５，６−ジヒドロベンゾ［ｆ］イミダゾ［１，２−ｄ］［１，４］オキサゼピン−９−イル）−１Ｈ−ピラゾール−１−イル）−２−メチルプロパンアミドの多形、それらの生成方法及び薬学的使用
CN112237579B (zh) 药物组合及其用途
US20240197680A1 (en) Voruciclib dosing regimens and methods of treatment including the same
JP2026505728A (ja) ６－（３－（（５－クロロ－２－メトキシピリジン）－３－スルホンアミド）－２，６－ジフルオロフェニル）－ｎ－メチルイミダゾ［１，５－ａ］ピラジン－１－カルボキサミドの結晶形態及びその使用方法
JP2024067010A (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
CN117043159A (zh) Kras突变型癌症的治疗
HK40103356A (zh) Kras突变型癌症的治疗
WO2024173833A1 (en) Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer
JP2024502130A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤の形態及び製剤
WO2026076001A1 (en) Compositions and methods for use in the treatment of cancer and other indications
HK40102219A (zh) 沃鲁西林给药方案和包含所述方案的治疗方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230614

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241119

Comment text: Request for Examination of Application